The result reflects declining sales, rising production costs, and fiscal pressure in a difficult market for the local pharmaceutical industry.
Revenue from customer contracts (net revenue) amounted to RON468.3 million, down 7% from RON506 million in 2024. The domestic market, which generates almost two-thirds of the revenue, was the main factor of weakness: sales fell by 12.5% to RON265.3 million, amid persistent inflation, declining purchasing power, and more cautious consumption of medicines, the company said. Antibiotice Iasi has a market capitalization of RON1.7 billion.
On foreign markets, revenue remained stable at RON202.6 million, with exports of finished products even increasing slightly by 3% to RON133.4 million. On the other hand, sales of active ingredients fell by 5% to RON70 million, mainly due to lower consumption in the US following tariff policy adjustments.
Overall, the gross margin fell to 64.3% from 66.7% a year ago, reflecting higher production costs. Raw material expenses rose by 8% to RON101.6 million, while energy and utility expenses increased by 31% to RON15 million. Salary expenses went up 10% to RON125.7 million, as a result of salary adjustments and the expansion of the teams involved in investment projects.
(English version by Loredana Fraitla-Cristescu)